Comprehensive pan-cancer analysis reveals CD70 as a promising therapeutic target and biomarker in clear cell renal cell carcinoma

This publication has 27 references indexed in Scilit:

• Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis
  European Urology Oncology, 2024
• Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
  Cell, 2024
• Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis of Individual Patient Data
  European Urology Focus, 2024
• Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
  The Lancet Oncology, 2024
• First and Second-line Treatments in Metastatic Renal Cell Carcinoma
  European Urology, 2024
• Ultrasound-driven facile fabrication of Pd doped SnO2 hierarchical superstructures: Structural, growth mechanism, dermatoglyphics, and anti-cancer activity
  Materials Science and Engineering: C, 2024
• METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer
  Cell Death & Differentiation, 2023
• Analysis of the Human Protein Atlas Weakly Supervised Single-Cell Classification competition
  Nature Methods, 2022
• The Immune Landscape of Cancer
  Immunity, 2018
• Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
  Scientific Reports, 2017